Zusammenfassung
Die infektiöse Endokarditis ist eine seltene Erkrankung mit hoher Morbidität und Letalität. Die Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) dokumentieren und bewerten die vorhandene Evidenz und geben Empfehlungen zur Prävention, Diagnostik und Therapie der infektiösen Endokarditis für den klinischen Alltag. Der vorliegende Beitrag enthält eine von der Paul-Ehrlich-Gesellschaft für Chemotherapie, der Deutschen Gesellschaft für Kardiologie, Herz- und Kreislaufforschung und weiteren Deutschen Fachgesellschaften initiierte, kommentierte Zusammenfassung des im Jahr 2009 erschienen Updates der ESC-Leitlinien.
Abstract
Infective endocarditis is a rare disease with high attributable morbidity and mortality. The Guidelines of the European Society of Cardiology (ESC) document and rate the existing evidence and provide recommendations for prevention, diagnosis, and treatment of infective endocarditis in daily clinical practice. The present manuscript contains an annotated summary of the 2009 update of these guidelines initiated by the Paul-Ehrlich Society for Chemotherapy, the German Society for Cardiology, and other German Medical Societies.
Literatur
Fowler VG Jr, Miro JM, Hoen B et al (2005) ICE Investigators. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012–3021
Murdoch DR, Corey GR, Hoen B et al (2009) International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169:463–473
Wilson W, Taubert KA, Gewitz M et al (2007) Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation 116:1736–1754
Naber CK, Al-Nawas B, Baumgartner H et al (2007) Prophylaxe der Infektiösen Endokarditis. Kardiologe 4:243–252
Nishimura RA, Carabello BA, Faxon DP et al (2008) ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis. J Am Coll Cardiol 52:676–685
Richey R, Wray D, Stokes T (2008) Guideline Development Group. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ 336:770–771
Habib G, Hoen B, Tornos P et al (2009) Guidelines on the prevention, diagnosis, and treatment of infective endocarditis. Eur Heart J 30:2369–2413
Horstkotte D, Follath F, Gutschik E et al (2004) Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European Society of Cardiology. Eur Heart J 25:267–276
Roberts GJ, Simmons NB, Longhurst P, Hewitt PB (1998) Bacteraemia following local anaesthetic injections in children. Br Dent J 185:295–298
Daniel WG, Mügge A, Martin RP et al (1991) Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 324:795–800
Kini V, Logani S, Ky B et al (2010) Transthoracic and transesophageal echocardiography for the indication of suspected infective endocarditis: vegetations, blood cultures and imaging. J Am Soc Echocardiogr (Epub ahead of print)
Naber CK, Erbel R (2007) Infective endocarditis with negative blood cultures. Int J Antimicrob Agents. 30:S32–S36
Fenollar F, Raoult D (2007) Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. Int J Antimicrob Agents 30(Suppl 1):S7–S15
Durack DT, Lukes AS, Bright DK (1994) New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med 96:200–209
Falagas ME, Matthaiou DK, Bliziotis IA (2006) The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 57:639–647
Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L (2004) Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328:668
Cosgrove SE, Vigliani GA, Fowler VG Jr et al (2009) Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48:713–721
Fowler VG Jr, Boucher HW, Corey GR et al (2006) S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665
Stryjewski ME, Szczech LA, Benjamin DK Jr et al (2007) Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44:190–196
Kim SH, Kim KH, Kim HB et al (2008) Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 52:192–197
Woodford N, Johnson AP, Morrison D, Speller DC (1995) Current perspectives on glycopeptide resistance. Clin Microbiol Rev 8:585–615
Soriano A, Marco F, Martínez JA et al (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193–200
Naber CK, Baddour LM, Giamarellos-Bourboulis EJ et al (2009) Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis 48(Suppl 4):S260–S270
Appelbaum PC (2007) Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 30:398–408
Bae IG, Federspiel JJ, Miró JM et al (2009) International collaboration on endocarditis-microbiology investigator. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 200:1355–1366
Agarwal VK, McHutchison JG, Hoofnagle JH (2010) Drug-induced liver injury network.important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol (Epub ahead of print)
Amodeo MR, Clulow T, Lainchbury J et al (2009) Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes. J Infect 59:387–393
Dickerman SA, Abrutyn E, Barsic B et al (2007) The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 154:1086–1094
Wang A, Athan E, Pappas PA et al (2007) Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297:1354–1361
Wang A, Pappas P, Anstrom KJ et al (2005) The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. Am Heart J 150:1086–1091
Interessenkonflikt
Keine Angaben.
Rights and permissions
About this article
Cite this article
Al-Nawas, B., Block, M., Ertl, G. et al. Kommentierte Zusammenfassung der Leitlinien der European Society of Cardiology zur Infektiösen Endokarditis (Neuauflage 2009). Kardiologe 4, 285–294 (2010). https://doi.org/10.1007/s12181-010-0282-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12181-010-0282-2